文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

宫颈癌放化疗联合图像引导自适应近距离放疗后的肠道并发症:EMBRACE研究中医生与患者报告的结果

Bowel morbidity following radiochemotherapy and image-guided adaptive brachytherapy for cervical cancer: Physician- and patient reported outcome from the EMBRACE study.
PubMed 文献 · Radiother Oncol · 2018-06-04

研究基于多中心EMBRACE研究,前瞻性评估1176例局部晚期宫颈癌患者接受MRI引导自适应近距离放疗后的晚期肠道并发症。3年和5年肠道并发症3-4级 actuarial 发生率分别为5.0%和5.9%,包括狭窄/缩窄/瘘管发生率为2.0%和2.6%;1-2级并发症患病率在随访期间为28-33%,腹泻和腹胀最常见。患者报告结果揭示腹泻(≥「有一点」)从基线26%升至3个月37%并持续升高,控制排便困难从基线11%升至3个月26%并随时间逐渐加重,而便秘和腹部绞痛在治疗后改善。

要点

  • 3年和5年肠道并发症3-4级发生率分别为5.0%和5.9%,狭窄/缩窄/瘘管为2.0%和2.6%。
  • 1-2级肠道并发症患病率在随访期间为28-33%,腹泻和腹胀最常见。
  • 患者报告腹泻(≥「有一点」)从基线26%升至3个月37%并持续,控制排便困难从11%升至26%并逐渐加重。

核心结论

  • 该大型局部晚期宫颈癌队列中肠道并发症在严重/危及生命事件方面有限,但轻中度腹泻、腹胀和失禁普遍存在,患者报告结果提示 considerable 且具有临床相关性的负担。
  • 基于治疗相关并发症的范围和表现模式的关键知识将服务于未来的患者管理。

研究设计与样本

  • 多中心EMBRACE研究,前瞻性评估局部晚期宫颈癌患者接受MRI引导自适应近距离放疗后的晚期肠道并发症。
  • 共分析1176例患者,医生报告并发症(CTCAE v.3.0)和患者报告结果(EORTC QLQ C30/CX24)在基线和定期随访时评估。

主要发现

  • 3年和5年肠道并发症3-4级 actuarial 发生率分别为5.0%和5.9%,包括狭窄/缩窄/瘘管发生率为2.0%和2.6%。
  • 1-2级并发症患病率在随访期间为28-33%,腹泻和腹胀最常报告,3个月后显著增加并在随访期间持续升高;失禁随时间逐渐加重。
  • 患者报告结果显示高患病率:腹泻≥「有一点」从基线26%升至3个月37%并持续升高;控制排便困难从基线11%升至3个月26%并随时间逐渐加重;便秘和腹部绞痛在治疗后改善。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/PURPOSE: This study describes late bowel morbidity prospectively assessed in the multi-institutional EMBRACE study on MRI-guided adaptive brachytherapy in locally advanced cervical cancer (LACC). MATERIALS/METHODS: A total of 1176 patients were analyzed. Physician reported morbidity (CTCAE v.3.0) and patient reported outcome (PRO) (EORTC QLQ C30/CX24) were assessed at baseline and at regular follow-up. RESULTS: At 3/5 years the actuarial incidence of bowel morbidity grade 3-4 was 5.0%/5.9%, including incidence of stenosis/stricture/fistula of 2.0%/2.6%. Grade 1-2 morbidity was pronounced with prevalence rates of 28-33% during follow-up. Diarrhea and flatulence were most frequently reported, significantly increased after 3 months and remained elevated during follow-up. Incontinence gradually worsened with time. PRO revealed high prevalence rates. Diarrhea ≥"a little" increased from 26% to 37% at baseline to 3 months and remained elevated, difficulty in controlling bowel increased from 11% to 26% at baseline to 3 months gradually worsening with time. Constipation and abdominal cramps improved after treatment. CONCLUSION: Bowel morbidity reported in this large cohort of LACC patients was limited regarding severe/life-threatening events. Mild-moderate diarrhea, flatulence and incontinence were prevalent after treatment with PROs indicating a considerable and clinically relevant burden. Critical knowledge based on the extent and manifestation pattern of treatment-related morbidity will serve future patient management.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Jensen NBK, Pötter R, Kirchheiner K, et al. Bowel morbidity following radiochemotherapy and image-guided adaptive brachytherapy for cervical cancer: Physician- and patient reported outcome from the EMBRACE study. Radiother Oncol. 2018. PMID: 29880222. doi:10.1016/j.radonc.2018.05.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。